Marquis LM, et al. - Researchers conducted this retrospective chart review to assess the impacts of switching to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) refractory to aflibercept treatment and to identify predictive factors for switch response. The sample consisted of 26 patients (32 eyes) with refractory nAMD, who switched from monthly intravitreal aflibercept treatment (≥ 6 months) to ranibizumab. No significant change has been found for visual acuity. Findings suggested that patients with nAMD refractory to aflibercept benefit from switching to ranibizumab, especially those whose condition deteriorated before the switch. This can be explained by drug tolerance to aflibercept.  No association with preceding switch has been found. The findings can encourage better decision making in the care, potentially improving patient outcomes.